CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands		6 Months Ended
		Jun. 30, 2025	Jun. 30, 2024
Cash flows from operating activities
Net income (loss) including noncontrolling interests		$ 19,055	$ (114,341)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Equity method loss (income)		2,446	(86)
Depreciation and amortization		15,315	13,359
Share-based compensation		31,400	33,519
Fair value adjustment to warrant liability		1,578	(1,571)
Impairment loss on investments in loans and securities	[1]	54,605	80,046
Gain on sale of investments in loans and securities		(8,690)	0
Amortization of deferred costs		5,843	1,250
Write-off of capitalized software		0	2,561
Loss on foreign exchange		1,311	186
Change in operating assets and liabilities:
Fees and other receivables	[1]	(22,132)	(11,614)
Accrued interest on investments	[1]	(15,246)	(10,204)
Prepaid expenses and other assets		9,628	998
Right-of-use assets		3,035	3,879
Accounts payable		2,108	6,071
Accrued expenses and other liabilities		(5,842)	7,793
Operating lease liability		(3,001)	(3,205)
Income taxes		364	18,363
Net cash provided by operating activities		91,777	27,004
Proceeds from the sale/maturity/prepayment of:
Investments in loans and securities	[1]	129,350	75,779
Acquisition of Theorem Technology, Inc., net of cash acquired		159	0
Payments for the purchase of:
Investments in loans and securities		(274,125)	(408,459)
Property and equipment		(7,576)	(9,525)
Equity method and other investments		0	(125)
Net cash used in investing activities		(152,192)	(342,330)
Cash flows from financing activities
Proceeds from sale of ordinary shares, net of issuance costs		0	89,956
Proceeds from long-term debt		0	244,725
Proceeds from secured borrowing		244,894	207,317
Proceeds received from noncontrolling interests		0	2,815
Proceeds from revolving credit facility		0	44,000
Proceeds from exercise of stock options, warrants and contributions to ESPP		3,977	759
Proceeds from issuance of ordinary shares from the Equity Financing Purchase Agreement		0	5,338
Distributions made to noncontrolling interests		(8,420)	(5,318)
Payments made to revolving credit facility		0	(134,000)
Payments made to secured borrowing		(156,924)	(78,809)
Payments made to long-term debt		(8,875)	(6,375)
Debt issuance costs		0	(7,974)
Net cash provided by financing activities		74,652	362,434
Effect of exchange rate changes on cash, cash equivalents and restricted cash		1,279	(1,723)
Net increase in cash, cash equivalents and restricted cash		15,516	45,385
Cash, cash equivalents and restricted cash, beginning of period		226,518	222,541
Cash, cash equivalents and restricted cash, end of period		242,034	267,926
Reconciliation of cash, cash equivalents, and restricted cash within the unaudited condensed consolidated balance sheet to the amounts shown in the statements of cash flow above:
Cash and cash equivalents		182,986	233,593
Restricted cash - current		23,845	17,469
Restricted cash - non-current		35,203	16,864
Total cash, cash equivalents, and restricted cash		$ 242,034	$ 267,926

[1] (1) Accrued interest receivable of $14.3 million, previously reported within “Fee and other receivables” as of December 31, 2024, has been reclassified to “Investment in loans and securities” to conform to the current period’s presentation and six month ended June 30, 2024 amounts have been reclassified to conform to the current period presentation.